tuberculosis%20-%20pulmonary%20(pediatric)
TUBERCULOSIS - PULMONARY (PEDIATRIC)
Tuberculosis (TB) is caused by Mycobacterium tuberculosis, a gram-positive bacteria with slow growth rate that is enhanced by 6-8% carbon dioxide and temperature of 35-40ºC.
It is primarily transmitted through airborne route.
The number of tubercle bacilli expelled in the air by a TB infected person is directly related to their infectiousness.
TB transmission is rare in children <10 years old due to their inability to expectorate sputum and low TB bacilli load in their sputum.
TB infection in children is usually obtained from an infectious adolescent or adult depending on the closeness and length of contact and the index case's severity of lung involvement and infectiousness.

Monitoring

  • Each patient should be assessed by individual country’s National Tuberculosis Program at the following intervals:
    • 2 weeks after initiation of treatment
    • At the end of intensive phase
    • Every 2 months until the completion of treatment
  • Assessment during follow-up should include symptoms evaluation, treatment adherence assessment, adverse drug reactions & weight management
  • Perform sputum smear at the end of the 2nd month in patient who was smear positive at diagnosis
  • Repeat sputum exam should be performed at months 3 of therapy if sputum microscopy was positive at end of 2 months of treatment
    • Line probe assay or Xpert MTB/RIF for repeat exam is highly recommended
  • Since patients have a slow radiological response to treatment, repeat chest X-ray is not routinely required
  • Adverse drug reactions are less common compared in adults
  • For patients on Ethambutol, monthly evaluations of visual acuity & color discrimination are advised
Multi-Drug Resistant TB
  • Smear sputum microscopy & culture should be performed monthly until 3 consecutive negative results are obtained
  • Follow-up sputum culture should be performed every 2-3 months
Drug-induced Hepatitis
  • Usually seen with Isoniazid, Rifampicin or Pyrazinamide therapy
  • Routine measurement of liver function tests is not routinely necessary during therapy unless there’s occurrence of jaundice, hepatomegaly or liver tenderness
Pyridoxine Deficiency
  • Commonly seen with Isoniazid therapy
  • Oral Pyridoxine is recommended in the following patients: Severely malnourished, HIV-infected, breastfeeding & pregnant adolescents
    • Supplementation of 5-10 mg/day is recommended
Orange-red Color Discoloration of Body Secretions
  • Associated with Rifampicin therapy
  • Benign in nature; reassure patient & parent

Prevention

Vaccination
Bacille-Calmette-Guerin (BCG)
  • Prevents life-threatening forms of tuberculosis (TB)
    • Has significant protective effect of about 50-80% for disseminated or miliary disease
  • Protective effect of BCG against pulmonary tuberculosis (PTB) is variable
  • Not recommended in immunocompromised patients
  • Multiple BCG vaccination is not recommended

Isoniazid Preventive Therapy

  • Reduces the risk of developing PTB by ~90% with good adherence
  • Recommended for patients <5 years of age presumed to have latent TB infection due to close contact with smear positive TB or human immunodeficiency virus (HIV) positive patient
  • Recommended Isoniazid dosage is 10 mg/kg/day PO once daily x 6 months
  • Follow-up is done every 2 months until treatment is complete
  • The addition of Rifampicin in Isoniazid monotherapy given for 3 months has been shown to be as effective as Isoniazid monotherapy
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS JPOG - Malaysia digital copy today!
DOWNLOAD
Editor's Recommendations
Most Read Articles
Elaine Soliven, 17 Aug 2017
Probiotic supplementation during the first 6 months of life does not reduce the incidence of eczema or asthma later in childhood, according to the randomized controlled TIPS* study.